62 results about "Retinal degeneration" patented technology

Compounds, compositions and methods for the treatment of retinal degenerative diseases, such as retinitis pigmentosa, Leber's congenital Amaurosis, Syndromic retinal degenerations, age-related macular degeneration and Usher Syndrome, and hearing loss associated with Usher Syndrome are described herein.

This invention relates to the expression method of adeno-associated virus-mediated gene in retinal cells. This invention can significantly improve the transfer efficiency and gene expression level of adeno-associated virus-mediated gene in retinal cells by using a combination of different types of adeno-associated virus, and has no toxic or side effect. Experimental results show that at a certain dosage range, replication-competent adenovirus and replication-defective adenovirus can significantly accelerate AAV2-mediated gene expression, and no cell lesion is observed. This invention can be used for gene treatment of ocular fundus diseases, such as retinosis, maculopathy, diabetic retinopathy, uveitis, choroidal neovascularization, optic nerve degeneration and damage.

The invention relates to a composition for improving vision. The composition is prepared by raw materials consisting of components of butterflybush flower, chrysanthemum, semen cassiae, ginseng, fructus ligustri lucidi, coptis chinensis, radix ophiopogonis, poria cocos and moutan bark. The composition disclosed by the invention can be applied to people which use a computer for a long time, to people which usually drive at night, to people which watch television and use a game machine for a long time, and to people which worry about vision loss simultaneously, and has a remarkable effect on the patients with the diseases such as retinopathy and cataract caused by myopia, hyperopia, presbyopia, retinal degeneration, nyctalopia, macular degeneration, glaucoma, senile cataract and diabetes mellitus. Lots of clinical applications indicate that a purpose of thoroughly radical cure is realized for many patients in a short time, and the cure rate is more than 97.2%.

Bioprosthetic retinal grafts (or devices) comprising stem cell derived tissues and/or cells may be used to slow the progression of retinal degenerative disease, slow the progression of retinal degenerative disease after traumatic injury, slow the progression of age related macular degeneration (AMD), prevent retinal degenerative disease, prevent retinal degenerative disease after traumatic injury,prevent AMD, restore retinal pigment epithelium (RPE), photoreceptor cells (PRCs) and retinal ganglion cells (RGCs) lost from disease, injury or genetic abnormalities, increasing RPE, PRCs and RCGs,treat RPE, PRCs and RCG defects in a subject, or for other purposes. Bioprosthetic retinal grafts may comprise a bioprosthetic carrier or scaffold suitable for implantation into the ocular space of asubject's eye, to form a bioprosthetic retinal patch. In certain embodiments, the bioprosthetic retinal patch may comprise multiple pieces of stem cell derived tissues or cells on a carrier or scaffold, which may be used to treat large areas of retinal degeneration or damage, or for other purposes.

This invention relates to novel method of treating or ameliorating a retinal disease or disorder or retinal degradation in a subject and a novel method of restoring retinal pigment epithelium cell compromising the administration of a one or more compounds which modulate Nox4, formation of radical oxygen species, serine protease, a dopamine receptor, NF-kB, mTOR, AMPK, RPE epithelial to mesenchymal transition, RPE dedifferentiation, or one or more Rho GTPases; and kits for administration of the methods.

The present invention relates to compounds of general formula I wherein R¹, R², R³ and R⁴ are as defined herein which maybe used for the treatment of schizophrenia, obsessive-compulsive

personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, cognitive impairment, chemotherapy-induced cognitive dysfunction (“chemobrain”), Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, and disturbances due to radiation therapy, chronic stress, optic neuropathy or macular degeneration, or abuse of neuro-active drugs, selected from alcohol, opiates, methamphetamine, phencyclidine and cocaine.

According to the invention, a CRISPR gene editing system and an AAV transduction system are utilized to directly knock out an RHO gene from adult macaque retinal photoreceptor cells so as to simulateretinal degeneration degeneration caused by hereditary RHO mutation, and a macaque retinal pigment degeneration (RP) animal model is constructed within 3-6 months. The model can promote research and treatment of human RP diseases.

The present invention relates to a Pde6b-deficient animal model of retinal degeneration produced by engineered endonucleases, and a method for producing the same. In the animal model of retinal degeneration according to the present invention, only a specific target gene can be removed using engineered endonucleases, so that mutagenesis can be stably achieved. In addition, it is possible to produce a congenital animal model through genetic manipulation at the embryonic stage rather than through acquired factors, which allows for production of an animal model that uniformly exhibits symptoms of the disease in question without being influenced by other factors.

The present disclosure provides in vitro methods for determining the potency of a cell-based therapy or treatment. In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, comprising (or comprising use of) quantitative in vitro assays for determining the potency of cell-based therapies or treatments, including those used in the treatment of retinal degeneration.

The instant invention provides methods and compositions related to discovery of Free Fatty Acid Receptor 1 (FFA1) as a therapeutic target for treatment or prevention of diseases or disorders of neurons that are characterized by angiogenesis, or of vascular diseases of the eye, retinal degeneration and/or tumors more generally. Therapeutic and/or prophylactic uses and compositions of known FFA1 inhibitors, including small molecules and nucleic acid agents, are described. Methods for identification of novel FFA1 inhibitors are also provided.

Retinal detachment sometimes occurs during the aging process of retinal degeneration 6 model mouse (rd6 model mouse). The present invention provides a method for obtaining a retinal degeneration (rd) model mouse having a low risk of causing retinal detachment, including: acquiring tissue data about a retinal tissue in an rd model mouse by using a retinal examination means; determining whether or not the tissue data meets an evaluation criterion; and selecting the rd model mouse, the tissue data of which meets the evaluation criterion.

The invention provides application of luteolin-7-Oglucoside to preparation of a medicine for treating diseases caused by retinal degeneration, and belongs to the technical field of ophthalmic diseasetreatment. The result shows that the luteolin-7-O-glucoside can be used for treating retinopathy caused by retinal degeneration.